Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7007—Drug-containing films, membranes or sheets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• Buprenorphine is a partial ⁇ -opiate receptor agonist, an ORLl/nociceptin receptor agonist with high affinity, and slow association and dissociation from the receptors, and a ⁇ -opiate receptor antagonist. Transmucosal bioavailability of buprenorphine is greater than its oral bioavailability, and, as a result, buprenorphine has been initially developed and marketed as a sublingual dosage form. Buprenorphine has been generally available as Temgesic ® 0.2 mg sublingual tablets and as Buprenex ® in a 0.3 mg/ml parenteral formulation, both indicated for the treatment of moderate to severe pain.
• naloxone an opioid antagonist
• the addition of naloxone to buprenorphine decreases the parenteral abuse potential of buprenorphine in opioid dependent subjects, as injected naloxone precipitates withdrawal by displacing the non-buprenorphine opioid from the receptor sites and blocking those sites from buprenorphine occupancy.
• Human laboratory studies have been conducted to test different dosage ratios of buprenorphine and naloxone (Fudala P.J. et al.
• FIGURE 1 is a schematic representation of exemplary embodiments of the present invention.
• FIGURE 2 is a graph showing assessment of dose-proportionality of buprenorphine C max after administration of the devices of the invention containing 0.875/0.15 mg, 3.5/0.6 mg and 5.25/0.9 mg of buprenorphine/naloxone as described in Example 4.
• FIGURE 3 is a graph showing assessment of dose-proportionality of buprenorphine AUCM after administration of the devices of the invention containing 0.875/0.15 mg, 3.5/0.6 mg and 5.25/0.9 mg of buprenorphine/naloxone as described in Example 4.
• FIGURE 4 is a graph showing COWS total scores recorded within 1 hour of subjects receiving study medication as a part of Naloxone Withdrawal Study as described in Example 5.
• FIGURE 5 is a graph showing changes in blood pressure, heart rate and oxygen saturation in subjects receiving study medication as a part of Naloxone Withdrawal Study as described in Example 5.
• the present invention is based, at least in part, on the discovery that bioavailability of an opioid agonist, e.g. , buprenorphine, disposed in the mucoadhesive layer of a two-layered, abuse-resistant transmucosal drug delivery device is not only affected by the pH of the mucoadhesive layer, but is also affected by the pH of the backing layer that resides on the lingual side of the bi-layer film.
• This layer may or may not contain an opioid antagonist, however in the preferred embodiment of the composition of the backing layer, it does include an opioid antagonist such as naloxone.
• both the pH of the mucoadhesive layer and the pH of the backing layer may be chosen such that the absorption of buprenorphine from the mucoadhesive layer is similar or higher than absorption from the mucoadhesive layer of a device with an unbuffered backing layer, while the absorption of naloxone, if present in the backing layer, is impeded.
• the mucoadhesive devices with buffered backing layer may comprise smaller doses of naloxone, while still providing abuse deterrence.
• the dose of naloxone is lowered, such that the w/w buprenorphine to naloxone ratio is higher than the ratio of 4:1, accepted in the art as being effective for providing abuse deterrence.
• the w/w buprenorphine to naloxone ratio present in the mucoadhesive device of the invention is between 4:1 and 10:1.
• the w/w buprenorphine to naloxone ratio is 6:1.
• Such a device is advantageous because it can provide effective abuse deterrence at a lower naloxone dose.
• the amount of naloxone required to precipitate withdrawal is as low as 0.1 mg when abused by injection.
• the maximum ratio of buprenorphine dose to naloxone is 10:1 and can be as low at 1:1.
• the ratio of buprenorphine dose to naloxone is 10:1 to 4: 1. In a specific embodiment, the ratio is 6:1.
• the present invention provides an abuse deterrent mucoadhesive device for use in managing pain or opioid dependence, the device comprising: a mucoadhesive layer comprising buprenorphine buffered to a pH of between about 4.0 and about 6.0; and a backing layer buffered to a pH between about 4.0 and about 4.8.
• the absorption of buprenorphine through the oral mucosal membrane is optimized and a therapeutically effective dose of buprenorphine is provided.
• the backing layer comprises naloxone.
• the w/w ratio of buprenorphine to naloxone present in the device is between 1:1 and 10: 1. In some embodiments, the ratio is between about 4:1 and 10:1. In a preferred embodiment, the w/w ratio of buprenorphine to naloxone present in the device is 6:1.
• the present invention provides an abuse deterrent mucoadhesive device for use in managing pain or opioid dependence, the device comprising: a mucoadhesive layer comprising buprenorphine buffered to a pH of between about 4.0 and about 6.0; and a backing layer buffered to a pH between about 4.0 and about 4.8; wherein bioavailability of buprenorphine absorbed from the device is greater than 40%.
• the bioavailability is about 60%. In some embodiments, the bioavailability is about 65%. In some embodiments, the
• bioavailability is about 75%.
• the mucoadhesive layer is buffered to a pH of between about 4.50 and about 5.50 and the backing layer is buffered to a pH of between about 4.10 and about 4.4. In a preferred embodiment, the mucoadhesive layer is buffered to a pH of about 4.75 and the backing layer is buffered to a pH of about 4.25.
• the device comprises about 0.075-12 mg of
• the amount of buprenorphine is 0.15-12 mg of buprenorphine.
• the device also comprises about 0.0125-2 mg of naloxone.
• the amount of naloxone is about 0.1-2 mg.
• the bioavailability of buprenorphine absorbed from the device is greater than 40%.
• the present invention provides an abuse deterrent mucoadhesive device for use in managing pain or opioid dependence, the device comprising: a mucoadhesive layer comprising buprenorphine and buffered to a first pH; a backing layer buffered to a second pH; the second pH selected such that the transmucosal delivery of buprenorphine is not impeded, such that the bioavailability of buprenophine is greater than 40%.
• the backing layer comprises naloxone, and the delivery of naloxone is impeded.
• the invention also provides an abuse deterrent mucoadhesive device for use in managing pain or opioid dependence, the device comprising: a mucoadhesive layer comprising buprenorphine and buffered to a first pH, a backing layer buffered to a second pH, the first pH and the second pH selected such that the unidirectional delivery gradient of buprenorphine toward the mucosa is not impeded, such that the total bioavailability of buprenophine provided by the device is similar to the total bioavailability of buprenorphine provided by the same device wherein the pH of the backing layer is not adjusted.
• the backing layer comprises naloxone, and the delivery of naloxone is impeded.
• an abuse deterrent mucoadhesive device for use in managing pain or opioid dependence comprises: a mucoadhesive layer comprising buprenorphine and buffered to a first pH and a backing layer buffered to a second pH; wherein the first pH is between about 4.0 and about 6.0; wherein the second pH is between about 4.0 and about 4.8.
• the backing layer comprises naloxone.
• buprenorphine and naloxone disposed in the device are present in w/w ratio of about 4:1 to about 10:1 of buprenorphine:naloxone. In one embodiment, the ratio is about 6:1.
• the first pH is between about 4.50 and about 5.50 and the second pH is between about 4.10 and about 4.4. In a specific embodiment, the first pH is about 4.75 and the second pH is about 4.25.
• the device comprises about 0.075 to 12 mg of buprenorphine and about 0.0125-2 mg of naloxone.
• an abuse deterrent mucoadhesive device for use in managing pain or opioid dependence comprises: a mucoadhesive layer comprising buprenorphine and buffered to a first pH and a backing layer buffered to a second pH; wherein the first pH is between about 4.0 and about 6.0; wherein the second pH is between about 4.0 and about 4.8; and wherein bioavailability of buprenorphine absorbed from the device is greater than 40%.
• the backing layer comprises naloxone.
• the first pH is between about 4.50 and about 5.50 and the second pH is between about 4.10 and about 4.4. In a specific embodiment, the first pH is about 4.75 and the second pH is about 4.25. In some embodiments, the device comprises about 0.075 to 12 mg of buprenorphine and about 0.0125-2 mg of naloxone.
• the abuse deterrent mucoadhesive device for use in managing pain or opioid dependence comprises: a mucoadhesive layer comprising buprenorphine and buffered to a first pH and a backing layer comprising naloxone and buffered to a second pH; wherein the first pH is about 4.75; wherein the second pH is about 4.25; and wherein buprenorphine and naloxone disposed in the device are present in w/w ratio of about 6:1 of buprenorphine: naloxone.
• methods of treating pain or managing opioid dependence in a subject are also provided.
• the methods generally comprise administering to a subject in need thereof an abuse deterrent mucoadhesive device of the invention, such that pain is treated or opioid dependence is managed in a subject.
• the articles “a” and “an” mean “one or more” or “at least one,” unless otherwise indicated. That is, reference to any element of the present invention by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present.
• the term "absorption” refers to the process of a substance, such as a drug, entering the bloodstream. Absorption can be measured by pharmacokinetic parameters, such as AUCM and C MAX .
• acute pain refers to pain characterized by a short duration, e.g. , three to six months. Acute pain is typically associated with tissue damage, and manifests in ways that can be easily described and observed. It can, for example, cause sweating or increased heart rate. Acute pain can also increase over time, and/or occur intermittently.
• bioavailability is as defined in 21 CFR Section 320.1 and refers to the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action.
• bioavailable refers to the total bioavailability including amounts that are transmitted via the mucosal membrane (i.e., transmucosally) and through the GI tract.
• absolute bioavailability refers to a fraction of a drug absorbed through non- intravenous administration (i.e.
• the mucoadhesive devices of the present invention provide absolute bioavailability of the opioid agonist buprenorphine that is equal to or greater than 40%, e.g.
• bioequivalence or “bioequivalent” is as defined in 21 CFR Section 320.1, and means the absence of a significant difference in the rate and extent of absorption of an active ingredient or active moiety in one pharmaceutical product and another.
• the pharmacokinetic parameters C max and AUC for bioequivalent actives fall within the 80%-125% range of each other.
• the devices of the present invention may be bioequivalent to Suboxone® sublingual tablet. Pharmacokinetic parameters, e.g.
• Suboxone® sublingual tablets comprising 2.0/0.5 mg and 8.0/2.0 mg of buprenorphine/naloxone is contained in the product label for Suboxone®, which is incorporated herein by reference in its entirety.
• chronic pain refers to pain which persists beyond the usual recovery period for an injury or illness. Chronic pain can be constant or intermittent. Common causes of chronic pain include, but are not limited to, arthritis, cancer, Reflex Sympathetic Dystrophy Syndrome (RSDS), repetitive stress injuries, shingles, headaches, fibromyalgia, and diabetic neuropathy, lower back pain, neck and shoulder pain, moderate to severe osteoarthritis, and patients with severe migraine.
• RSDS Reflex Sympathetic Dystrophy Syndrome
• the term “buprenorphine” includes any pharmaceutically acceptable form of buprenorphine, including, but not limited to, salts, esters, and prodrugs thereof.
• the term “buprenorphine” refers to buprenorphine hydrochloride.
• the term “buprenorphine derivative” refers to compounds having similar structure and function to buprenorphine.
• Buprenorphine derivatives include, but are not limited to, etorphine and diprenorphine.
• General buprenorphine derivatives are described in WO 2008/011194, which is hereby incorporated by reference.
• naloxone includes any pharmaceutically acceptable form of naloxone, including, but not limited to, salts, esters, and prodrugs thereof.
• naloxone refers to naloxone hydrochloride.
• naloxone is represented by the following chemical structure:
• the term "mucoadhesive layer” or "polymeric diffusion environment” refers to an environment capable of allowing flux of a medicament to a mucosal surface upon creation of a gradient by adhesion of the polymeric diffusion environment to a mucosal surface. The flux of a transported medicament is
• the term "backing layer” or “non-adhesive polymeric environment” refers to an environment in the form of, e.g. , a layer or coating or barrier layer, capable of slowing, reducing or stopping flux of a medicament in its direction and does not adhere to surfaces in the oral cavity.
• the pH of the backing layer is adjusted, such as it stops flux of a medicament contained therein and in the mucoadhesive layer, except in the direction of the mucosa.
• the non-adhesive polymeric environment significantly slows flux of a medicament, e.g., enough so that little or no medicament is washed away by saliva.
• the non-adhesive polymeric environment slows or stops flux of a medicament, while allowing hydration of the polymeric diffusion environment e.g. , by saliva.
• the term "unidirectional gradient” refers to a gradient which allows for the flux of a medicament (e.g. , buprenorphine) through the device, e.g. , through a polymeric diffusion environment, in substantially one direction, e.g., to the mucosa of a subject.
• the polymeric diffusion environment may be a mucoadhesive polymeric diffusion environment in the form of a layer or film disposed adjacent to a backing layer or film.
• a gradient is created between the mucoadhesive polymeric diffusion environment and the mucosa, and the medicament flows from the mucoadhesive polymeric diffusion environment, substantially in one direction towards the mucosa.
• some flux of the medicament is not entirely unidirectional across the gradient; however, there is typically not free flux of the medicament in all directions.
• treating or “treatment” of a subject includes the administration of a drug to a subject with the purpose of preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder (e.g., to alleviate pain).
• subject refers to living organisms such as humans, dogs, cats, and other mammals.
• Administration of the medicaments included in the devices of the present invention can be carried out at dosages and for periods of time effective for treatment of a subject.
• the subject is a human.
• the pharmacokinetic profiles of the devices of the present invention are similar for male and female subjects.
• an "effective amount" of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
• transmucosal refers to any route of administration via a mucosal membrane. Examples include, but are not limited to, buccal, sublingual, nasal, vaginal, and rectal. In one embodiment, the administration is buccal. In one embodiment, the administration is sublingual. As used herein, the term “direct transmucosal” refers to mucosal administration via the oral mucosa, e.g. , buccal and/or sublingual.
• water erodable or “at least partially water erodable” refers to a substance that exhibits a water erodability ranging from negligible to completely water erodable.
• the substance may readily dissolve in water or may only partially dissolve in water with difficulty over a long period of time.
• the substance may exhibit a differing erodability in body fluids compared with water because of the more complex nature of body fluids.
• a substance that is negligibly erodable in water may show an erodability in body fluids that is slight to moderate.
• the erodability in water and body fluid may be approximately the same.
• the term "impeded" when used to describe the absorption or the delivery of the opioid antagonist from the abuse-resistant device refers to the absorption and/or delivery of said opioid antagonist that is insufficient to inhibit the effects of the opioid agonist comprised in the same device.
• addiction therapy as related to a subject includes the administration of a drug to a subject with the purpose of reducing the cravings for the addictive substance.
• abusive or “abusive manner” refers to uses of the devices beyond transmucosal administration such as by injecting or snorting.
• disposed refers to the uniform or non-uniform distribution of an element within another.
• Certain aspects of the present invention include methods for providing maintenance treatment for a subject addicted to opioids.
• buprenorphine maintenance is one of the most promising courses of action for addicted subjects in terms of long-term abstinence.
• Certain aspects of the present invention include methods for providing pain management and/or relief to a subject in need thereof.
• the pain can be any pain known in the art, caused by any disease, disorder, condition and/or circumstance and can be chronic pain or acute pain.
• the present invention is directed to abuse-resistant mucoadhesive delivery devices suitable for administration of an effective amount of an opioid drug to a subject, for the management of pain and/or opioid dependence.
• the device is capable of delivering the opioid agonist by means of a unidirectional gradient (i.e. flux that flows toward the mucosa) that is created upon application of the device to a mucosal surface.
• the devices of the present invention can include any combination or subcombination of ingredients, layers and/or compositions of, e.g. , the devices described in U.S. Pat. No. 6,159,498, U.S. Pat. No. 5,800,832, U.S. Pat. No. 6,585,997, U.S. Pat. No. 6,200,604, U.S. Pat. No. 6,759,059 and/or PCT Publication No. WO 05/06321. The contents of these patent and publications are incorporated herein by reference in their entireties. i. Mucoadhesive layer
• the mucoadhesive layer is a bioerodable or water- erodable mucoadhesive layer.
• the devices of the present invention include a bioerodable mucoadhesive layer which comprises a mucoadhesive polymeric diffusion environment. The device adheres to a mucosal surface of the subject within about 5 seconds following application.
• the mucoadhesive polymeric diffusion environment comprises an opioid agonist.
• the opioid agonist is
• the dose of buprenorphine that can be incorporated into the device of the present invention depends on the desired treatment dosage to be administered and can range from about 10 ⁇ g to about 20 mg of buprenorphine. In other embodiments related to the treatment of pain, the dose of buprenorphine can range from about 60 ⁇ g to about 6 mg. In some embodiments, the low dose of buprenorphine comprised in the mucoadhesive device of the invention is between about 0.075 and 12 mg of buprenorphine, e.g.
• the dose is 0.875 mg of buprenorphine. In another embodiment, the dose is 1.75 mg of buprenorphine. In another embodiment, the dose is 3.5 mg of buprenorphine. In yet another embodiment, the dose is 5.25 mg of buprenorphine.
• the mucoadhesive polymeric diffusion environment can include the drug, at least one pharmacologically acceptable polymer capable of bioadhesion (the "bioadhesive polymer”), and can optionally include at least one film- forming bioerodable or water-erodable polymer (the “film-forming polymer”).
• the mucoadhesive polymeric diffusion environment can be formed of a single polymer that acts as both the bioadhesive polymer and the first film-forming polymer.
• the mucoadhesive polymeric diffusion environment can include other film-forming water-erodable polymers and/or water- erodable plasticizers, such as glycerin and/or polyethylene glycol (PEG).
• the bioadhesive polymer of the mucoadhesive polymeric diffusion environment can include any water erodable substituted cellulosic polymer or substituted olefinic polymer wherein the substituents may be ionic or hydrogen bonding, such as carboxylic acid groups, hydroxyl alkyl groups, amine groups and amide groups.
• substituents may be ionic or hydrogen bonding
• carboxylic acid groups hydroxyl alkyl groups, amine groups and amide groups.
• a combination of alkyl and hydroxyalkyl groups will be preferred for provision of the bioadhesive character and the ratio of these two groups will have an effect upon water swellability and dispersability.
• Examples include polyacrylic acid (PAA), which can optionally be partially cross-linked, sodium carboxymethyl cellulose (NaCMC), moderately to highly substituted
• HPMC hydroxypropylmethyl cellulose
• PVP3 polyvinylpyrrolidone
• HEMC hydroxyethylmethyl cellulose
• bioadhesive polymer can be used as the bioadhesive polymer and the first film forming polymer as described above for a mucoadhesive polymeric diffusion environment formed of one polymer.
• bioadhesive polymers are preferred because they have good and instantaneous mucoadhesive properties in a dry, system state.
• the mucoadhesive polymeric diffusion environment e.g. , a bioerodable mucoadhesive layer
• a bioerodable mucoadhesive layer is generally comprised of water-erodable polymers which include, but are not limited to, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), polyacrylic acid (PAA) which may or may not be partially cross-linked, sodium carboxymethyl cellulose (NaCMC), and polyvinylpyrrolidone (PVP), or combinations thereof.
• HEC hydroxyethyl cellulose
• HPC hydroxypropyl cellulose
• HPMC hydroxypropylmethyl cellulose
• HEMC hydroxyethylmethyl cellulose
• PAA polyacrylic acid
• NaCMC sodium carboxymethyl cellulose
• PVP polyvinylpyrrolidone
• Similar film-forming water-erodable polymers can also be used.
• the film- forming water-erodable polymers can optionally be cross-linked and/or plasticized in order to alter its dissolution kinetics.
• the properties of the mucoadhesive polymeric diffusion environment are influenced by its pH.
• its pH is between about 4.0 and about 7.5.
• the pH is between 4.0 and 6.0, more specifically, between 4.5 and 5.5, and even more specifically, between 4.75 and 5.25.
• the pH is 4.75. It is to be understood that all values and ranges between these values and ranges are meant to be encompassed by the present invention.
• the pH of the mucoadhesive polymeric diffusion environment can be adjusted and/or maintained by methods including, but not limited to, the use of buffering agents, or by adjusting the composition of the device of the present invention.
• Buffering agents suitable for use with the present invention include, for example, phosphates, such as sodium phosphate; phosphates monobasic, such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; phosphates dibasic, such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; phosphates tribasic, such as trisodium phosphate; citrates, such as sodium citrate (anhydrous or dehydrate) and triethyl citrate; bicarbonates, such as sodium bicarbonate and potassium bicarbonate; acetates, such as sodium acetate, may be used.
• a single buffering agent e.g. , a dibasic buffering agent is used.
• a combination of buffering agents is employed, e.g. , a combination of a tri-basic buffering agent and a monobasic buffering agent.
• the amount of buffering agent is present in a composition used to make the mucoadhesive layer is about 1 to 20% of the amount of the agonist drug, e.g. , buprenorphine. ii. Backing layer
• the device further comprises at least one additional non-adhesive polymeric environment, e.g. , a backing layer.
• This layer is disposed adjacent to the mucoadhesive polymeric diffusion environment, e.g. , a backing layer, functions to facilitate the delivery of the opioid agonist, such as buprenorphine, to the mucosa.
• This additional layer may comprise the same or a different combination of polymers as the
• mucoadhesive polymeric diffusion environment or the non-adhesive polymeric diffusion environment.
• the backing layer includes an additional medicament, such as an opioid antagonist, to render the device of the invention abuse- resistant.
• the opioid antagonist is naloxone.
• the dose of naloxone that can be incorporated into the device of the present invention depends on the desired treatment dosage to be administered and can range from about 100 ⁇ g to 5 mg of naloxone for the treatment of dependence, and from 60 ⁇ g to 1.5 mg naloxone for the pain indication.
• the dose of naloxone is between about 0.0125 mg to about 2.0 mg of naloxone, e.g., 0.0125 mg, 0.0130 mg, 0.0135 mg, 0.0140 mg, 0.0145 mg, 0.0150 mg, 0.0155 mg, 0.0160 mg, 0.0165 mg, 0.0170 mg, 0.0175 mg, 0.0180 mg, 0.0185 mg, 0.0190 mg, 0.0195 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.145 mg, 0.2 mg, 0.29 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.58 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.87 mg, 0.9 mg, 1.0 mg, 1.1 mg, 1.2 mg, 1.3 mg, 1.4 mg, 1.5 mg, 1.6 mg, 1.7 mg, 1.8 mg, 1.9 mg or 2.0 mg of naloxone.
• the dose is 0.145 mg of naloxone. In another embodiment, the dose is 290 ⁇ g of naloxone. In another embodiment, the dose is 580 ⁇ g of naloxone. In yet another embodiment, the dose is 870 ⁇ g of naloxone.
• the amount of buprenorphine and the amount of naloxone disposed in the device are present in a ratio chosen such that the effect of buprenorphine is negated by naloxone if the mixture is injected or snorted. In such embodiment, buprenorphine and naloxone disposed in the device are present in a w/w ratio that ranges between 1 :4 and 1: 10. In a preferred embodiment, the w/w ratio of buprenorphine to naloxone is 1:4 to 1:6, wherein 1:6 is the most preferred embodiment.
• the backing layer functions as a barrier to facilitate a unidirectional flux of the medicament, e.g. , buprenorphine, disposed in the mucoadhesive layer.
• the medicament e.g. , buprenorphine
• the backing layer can serve an erodible polymer that facilitate absorption of buprenorphine in the orophyrangeal tissue.
• the non-adhesive polymeric environment may circumscribe the boundaries of the mucoadhesive polymeric diffusion environment thereby ensuring that medicament flows toward the mucosa.
• the backing layer (e.g. , a water-erodable non-adhesive backing layer) can further include at least one water erodable, film- forming polymer.
• This layer may optinally include a drug.
• the polymer or polymers can include polyethers and polyalcohols as well as hydrogen bonding cellulosic polymers having either hydroxyalkyl group substitution or hydroxyalkyl group and alkyl group substitution preferably with a moderate to high ratio of hydroxyalkyl to alkyl group. Examples include, but are not limited to, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC),
• the water-erodable non-adhesive backing layer component can optionally be cross-linked.
• the non-adhesive backing layer is free of cross-linked polymers. In a preferred embodiment of the device, the non-adhesive backing layer is free of polyacrylic acid. While not wishing to be bound by any specific theory, it is estimated that the residence time is reduced by the absence of said polyacrylic acid. For example, in certain embodiments, the residence time is between 15 and 30 minutes.
• the water erodable non-adhesive backing layer includes hydroxyethyl cellulose and hydroxypropyl cellulose.
• the devices of the present invention can include ingredients that are employed to, at least in part, provide a desired residence time. In some embodiments, this is a result of the selection of the appropriate backing layer formulation, providing a slower rate of erosion of the backing layer.
• the non-adhesive backing layer is further modified to render controlled erodability which can be accomplished by coating the backing layer film with a more hydrophobic polymer selected from a group of FDA approved EudragitTM polymers, ethyl cellulose, cellulose acetate phthalate, and hydroxyl propyl methyl cellulose phthalate, that are approved for use in other pharmaceutical dosage forms.
• hydrophobic polymers may be used, alone or in combination with other hydrophobic or hydrophilic polymers, provided that the layer derived from these polymers or combination of polymers erodes in a moist environment. Dissolution characteristics may be adjusted to modify the residence time and the release profile of a drug when included in the backing layer.
• any of the layers in the devices of the present invention may also contain a plasticizing agent, such as propylene glycol, polyethylene glycol, or glycerin in a small amount, 0 to 15% by weight, in order to improve the "flexibility" of this layer in the mouth and to adjust the erosion rate of the device.
• a plasticizing agent such as propylene glycol, polyethylene glycol, or glycerin in a small amount, 0 to 15% by weight, in order to improve the "flexibility" of this layer in the mouth and to adjust the erosion rate of the device.
• humectants such as hyaluronic acid, glycolic acid, and other alpha hydroxyl acids can also be added to improve the "softness" and "feel” of the device.
• colors and opacifiers may be added to help distinguish the resulting non-adhesive backing layer from the mucoadhesive polymeric diffusion environment.
• Some opacifers include titanium dioxide, zinc oxide, zirconium silicate, etc
• the device can also optionally include a pharmaceutically acceptable dissolution-rate-modifying agent, a pharmaceutically acceptable disintegration aid (e.g. , polyethylene glycol, dextran, polycarbophil, carboxymethyl cellulose, or poloxamers), a pharmaceutically acceptable plasticizer, a pharmaceutically acceptable coloring agent (e.g. , FD&C Blue #1), a pharmaceutically acceptable opacifier (e.g. , titanium dioxide), pharmaceutically acceptable anti-oxidant (e.g. , tocopherol acetate), a pharmaceutically acceptable system forming enhancer (e.g. , polyvinyl alcohol or polyvinyl pyrrolidone), a pharmaceutically acceptable preservative, flavorants (e.g.
• a pharmaceutically acceptable dissolution-rate-modifying agent e.g. , polyethylene glycol, dextran, polycarbophil, carboxymethyl cellulose, or poloxamers
• a pharmaceutically acceptable plasticizer e.g. , FD&C Blue #1
• saccharin and peppermint include saccharin and peppermint, neutralizing agents (e.g. , sodium hydroxide), buffering agents (e.g. , monobasic, or tribasic sodium phosphate), or combinations thereof.
• neutralizing agents e.g. , sodium hydroxide
• buffering agents e.g. , monobasic, or tribasic sodium phosphate
• these components are individually present at no more than about 1% of the final weight of the device, but the amount may vary depending on the other components of the device.
• the non-adhesive polymeric diffusion environment e.g. , the backing layer
• the pH of the backing layer is between 4.0 and 6.0, more specifically, between 4.2 and 4.7, and even more specifically, between 4.2 and 4.4. In one embodiment, the pH of the backing layer is 4.25. It is to be understood that all values and ranges between these values and ranges are meant to be encompassed by the present invention.
• the pH of the backing layer can be adjusted and/or maintained by methods including, but not limited to, the use of buffering agents, or by adjusting the composition of the device of the present invention.
• the properties of the polymeric diffusion environment are influenced by its buffering capacity.
• buffering agents are included in the mucoadhesive polymeric diffusion environment.
• Buffering agents suitable for use with the present invention include, for example, phosphates, such as sodium phosphate; phosphates monobasic, such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; phosphates dibasic, such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; phosphates tribasic, such as trisodium phosphate; citrates, such as sodium citrate (anhydrous or dehydrate) and triethyl citrate; bicarbonates, such as sodium bicarbonate and potassium bicarbonate; acetates, such as sodium acetate, may be used.
• a single buffering agent e.g. , a dibasic buffering agent is used.
• a combination of buffering agents is employed, e.g. , a combination of a tri-basic buffering agent and a monobasic buffering agent.
• the backing layer comprises the opioid antagonist.
• the backing layer comprises an opioid antagonist that is present as a microencapsulated particle with polymers.
• polymers include, but are not limited to alginates, polyethylene oxide, poly ethylene glycols, polylactide, polyglycolide, lactide-glycolide copolymers, poly-epsilon- caprolactone, polyorthoesters, polyanhydrides and derivatives, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropylmethyl cellulose, polyacrylic acid, and sodium carboxymethyl cellulose, poly vinyl acetate, poly vinyl alcohols, polyethylene glycol, polyethylene oxide, ethylene oxide-propylene oxide co-polymers, collagen and derivatives, gelatin, albumin, polyaminoacids and derivatives, polyphosphazenes, polysaccharides and derivatives, chitin, chitosan bioadhesive polymers, polyacrylic acid, polyvinyl pyrrolidone, sodium carboxymethyl cellulose and combinations
• the mucoadhesive layer for Formulations 1 and 3 is prepared using the same ingredients as for formulations 2 and 4, respectively, except that the amounts of all ingredients are adjusted in direct proportion to the amount of buprenorphine and the film size of 0.78 cm 2 .
• the mucoadhesive layer for Formulations 5 and 7 are prepared using the same ingredients as for Formulation 6, except that the amounts of all ingredients are adjusted in direct proportion to the amount of buprenorphine and film size of 0.9 cm 2 for formulation 5 and 5.37 cm 2 for Formulation 7.
• the backing layer for Formulations 1 and 3 is prepared using the same ingredients as for Formulations 2 and 4, respectively, except that the amounts of all ingredients are adjusted in direct proportion to the amount of naloxone and the film size of 0.78 cm 2 .
• the backing layer for Formulations 5 and 7 is prepared using the same ingredients as for Formulation 6, except that the amounts of all ingredients are adjusted in direct proportion to the amount of buprenorphine and film size of 0.9 cm 2 for Formulation 5 and 5.37 cm 2 for Formulation 7.
• pharmacokinetic analyses were collected pre-dose and 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes post-dose and at 8, 10, 12, 24 and 48 hours post-dose. Blood samples were analyzed using the established procedures utilizing liquid chromatography and mass spectrometry (LC/MS). The selected pharmacokinetic parameters for buprenorphine and free naloxone are shown in Tables 6 and 7.
• buprenorphine/naloxone was compared with those from a single device prepared according to formulation 6 that contained an equivalent dose of actives (3.5/0.6 mg buprenorphine/naloxone) .
• Naltrexone was co-administered approximately 12 hours and 30 minutes prior to and approximately 12 and 24 hours after the single study drug doses.
• Serial blood samples for pharmacokinetic analyses were collected pre-dose and 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 270, 300, 330 and 360 minutes post-dose and at 8, 10, 12, 24 and 48 hours post-dose. Blood samples were analyzed using the established procedures utilizing liquid chromatography and mass spectrometry (LC/MS). The selected pharmacokinetic parameters for buprenorphine and free naloxone are shown in Tables 8 and 9.
• the results of the study indicate that changing the w/w ratio of buprenorphine to naloxone from 4: 1 to 6: 1 results in decreased naloxone exposure that I s more in line with the exposure needed to precipitate withdrawal if abused but not so much as to precipitate the withdrawal if used as indicated.
• the results also indicate that C max and AUCinf of buprenorphine from formulations 5, 6 and 7 is dose proportional. Dose proportionality of buprenorphine C max and AUCM are also illustrated by the graphs shown in Figures 2 and 3, respectively.
• transmucosal devices of the invention that are prepared according to Formulations 1, 3 and 5 comprise relatively small doses of buprenorphine and naloxone (0.75 mg/0.19 mg and 0.875/0.15 mg buprenorphine/naloxone, as compared to 2 mg/0.5 mg buprenorphine/naloxone contained in the equivalent Suboxone® tablet). While the lower dose of the naloxone may be beneficial for the patient using the product correctly, it may not produce the expected aversive reaction experienced by those who are dependent on full-agonist opioids.
• the objective of the study was to determine the minimum effective dose of naloxone that will produce a withdrawal response when administered with a 0.75 mg dose of buprenorphine in opioid dependent subjects.
• the secondary objective of the study was to determine whether administration of a 0.75 mg dose of buprenorphine without naloxone will produce a withdrawal response in opioid dependent subjects.
• the study was designed to include a total of 12 adult subjects that completed the 4- period crossover. Subjects were eligible for inclusion in the study if all the following criteria applied: subjects experienced chronic moderate to severe non-cancer pain that has been treated > 100 mg morphine equivalents per day for at least 3 months prior to the study; subjects displayed signs and symptoms of withdrawal (i.e. , COWS score >5) following naloxone administration during the Naloxone Challenge.
• Eligible subject exhibited signs of withdrawal, e.g. , had a positive response (COWS > 5) to the Naloxone Withdrawal Test, following administration of up to eight 0.05 mg IV doses of naloxone.
• the Clinical Opiate Withdrawal Scale was used to evaluate symptoms of opioid withdrawal.
• the scale contains 11 items to rate signs and symptoms of opioid withdrawal including pulse rate, gastrointestinal upset, sweating, tremor, restlessness, yawning, pupil size, anxiety or irritability, bone or joint aches, gooseflesh skin, runny nose, tearing.
• Each symptom is rated on a unique scale.
• Total scores for the scale range from 0 to 48 with scores of 5-12 indicating mild withdrawal; scores of 13-24 indicating moderate withdrawal; scores of 25-36 indicating moderately severe withdrawal; and scores >36 indicating severe withdrawal.
• Descriptive statistics were used to summarize the results from the PD analyses at each timepoint for each treatment group, without formal statistical testing.
• a mixed effect model was fitted to the data for the change from baseline in total score where the model included factors for: the overall mean change; fixed effects due to sequence; treatment, time and period; and a random effect for subject nested within sequence.
• Subject data collected after rescue time i.e., time at which the subjects reaches COWS total score of 13 or more were excluded to minimize the confounding effect of rescue on the PD analyses.
• Time-to-Total score of >13 was calculated as time (hours) from first dose until the subject reports a total score of >13. Subjects who did not reach a total score of 13 or more were censored at 24 hours. This endpoint was summarized using the Kaplan-Meier method and 95% CI presented for median for each treatment arm.
• the number of subjects with COWS total score of at least 7 in the first hour post dose is shown on the left side of FIGURE 4.
• DEQ Drug Effect Questionnaire
• naloxone at doses of 0.1 and 0.2 mg provide an abuse deterrent effect to a 0.75 mg dose of buprenorphine when administered intravenously to opioid dependent subjects.

Priority Applications (17)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47712819

Family Applications (1)

Country Status (15)

Families Citing this family (18)

Citations (2)

Family Cites Families (131)

• 2012
  • 2012-08-20 CA CA3119258A patent/CA3119258A1/en not_active Abandoned
  • 2012-08-20 CN CN201280051202.8A patent/CN103889508B/zh active Active
  • 2012-08-20 JP JP2014526274A patent/JP6158810B2/ja active Active
  • 2012-08-20 CN CN201710706472.2A patent/CN107441067A/zh active Pending
  • 2012-08-20 KR KR1020147007036A patent/KR101944367B1/ko active IP Right Grant
  • 2012-08-20 SG SG11201401446RA patent/SG11201401446RA/en unknown
  • 2012-08-20 EA EA201490425A patent/EA033256B1/ru unknown
  • 2012-08-20 BR BR112014003651-9A patent/BR112014003651B1/pt active IP Right Grant
  • 2012-08-20 EP EP12823941.5A patent/EP2744572B1/en active Active
  • 2012-08-20 EA EA201991223A patent/EA201991223A1/ru unknown
  • 2012-08-20 US US13/590,094 patent/US8703177B2/en active Active
  • 2012-08-20 WO PCT/US2012/051618 patent/WO2013026064A1/en active Application Filing
  • 2012-08-20 SG SG10201610097WA patent/SG10201610097WA/en unknown
  • 2012-08-20 ES ES12823941.5T patent/ES2660116T3/es active Active
  • 2012-08-20 MX MX2014001873A patent/MX352959B/es active IP Right Grant
  • 2012-08-20 CA CA2845634A patent/CA2845634C/en active Active
  • 2012-08-20 AU AU2012296346A patent/AU2012296346A1/en not_active Abandoned
• 2014
  • 2014-02-16 IL IL230996A patent/IL230996B/en active IP Right Grant
  • 2014-09-29 US US14/499,651 patent/US20150246002A1/en not_active Abandoned
  • 2014-12-11 HK HK14112453.9A patent/HK1198958A1/xx not_active IP Right Cessation
• 2015
  • 2015-05-05 US US14/704,955 patent/US20160095821A1/en not_active Abandoned
• 2016
  • 2016-07-18 US US15/213,137 patent/US20160324849A1/en not_active Abandoned
  • 2016-07-18 US US15/213,051 patent/US20160339016A1/en not_active Abandoned
• 2017
  • 2017-06-08 JP JP2017113109A patent/JP2017193563A/ja not_active Withdrawn
  • 2017-11-13 US US15/810,705 patent/US20180064706A1/en not_active Abandoned
• 2018
  • 2018-01-17 AU AU2018200402A patent/AU2018200402B2/en not_active Ceased
  • 2018-07-09 US US16/030,439 patent/US20190000833A1/en not_active Abandoned
• 2019
  • 2019-02-04 US US16/266,513 patent/US20190240214A1/en not_active Abandoned
  • 2019-03-01 JP JP2019037264A patent/JP6657454B2/ja active Active
  • 2019-07-16 AU AU2019206022A patent/AU2019206022A1/en not_active Abandoned
  • 2019-10-28 US US16/665,473 patent/US20200129503A1/en not_active Abandoned
• 2020
  • 2020-02-05 JP JP2020017711A patent/JP2020079277A/ja active Pending
  • 2020-10-10 US US17/067,676 patent/US20220016109A1/en not_active Abandoned
• 2021
  • 2021-03-16 AU AU2021201650A patent/AU2021201650A1/en not_active Abandoned
• 2022
  • 2022-01-20 JP JP2022006949A patent/JP2022058678A/ja active Pending
• 2023
  • 2023-10-06 US US18/482,091 patent/US20240108615A1/en active Pending

Patent Citations (2)

Also Published As

Similar Documents

Legal Events